C4 Therapeutics, Inc. (CCCC) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 78.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $78.61M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $61.27M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $74.60M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $58.81M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $78.16M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $51.29M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $55.50M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $59.65M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $73.11M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $89.66M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $126.59M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $60.97M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $44.88M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $49.48M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $29.75M | (m) | (m) |
| 2022-09-30 | $313.65M | (m) | $49.55M | $264.10M | (m) |
| 2022-06-30 | $307.78M | (m) | $57.30M | $250.48M | (m) |
| 2022-03-31 | $291.17M | (m) | $46.00M | $245.17M | (m) |
| 2021-12-31 | $309.28M | (m) | $76.12M | $233.16M | (m) |
| 2021-09-30 | $402.07M | (m) | $162.75M | $239.33M | (m) |
| 2021-06-30 | $465.91M | (m) | $281.15M | $184.76M | (m) |
| 2021-03-31 | $313.48M | (m) | $94.91M | $218.57M | (m) |
| 2020-12-31 | $371.69M | (m) | $181.73M | $189.96M | (m) |
| 2020-09-30 | (m) | (m) | $63.43M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $107.65M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $73.86M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $90.55M | (m) | (m) |
| 2019-09-30 | (m) | (m) | $100.97M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |